Methylmalonic Acidaemia Pipeline Research Report 2023: Comprehensive Insights About 4+ Companies and 4+ Pipeline Drugs

DUBLIN, Dec. 13, 2023 /PRNewswire/ — The “Methylmalonic Acidaemia – Pipeline Insight, 2023” clinical trials has been added to  ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Methylmalonic Acidaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The companies and academics are working to assess challenges and seek opportunities that could influence Methylmalonic Acidaemia R&D. The therapies under development are focused on novel approaches to treat/improve Methylmalonic Acidaemia.

Methylmalonic Acidaemia Emerging Drugs Chapters

This segment of the Methylmalonic Acidaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Methylmalonic Acidaemia Emerging Drugs

HST5040: HemoShear Therapeutics

HST5040 is an investigational oral small molecule therapy being developed by HemoShear to reduce the levels of toxins associated with methylmalonic acidemia (MMA) and propionic acidemia (PA), rare genetic disorders caused by the deficiency of certain enzymes required to metabolize amino acids. HST5040 is formulated for convenient daily administration at home as a liquid taken either orally or through a gastrostomy tube. The FDA has granted HST5040 Orphan Drug, Fast Track and Rare Pediatric Disease designations for the treatment of MMA and PA.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Methylmalonic Acidemia.

Methylmalonic Acidaemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Methylmalonic Acidaemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Methylmalonic Acidaemia drugs.

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Methylmalonic Acidaemia drugs?How many Methylmalonic Acidaemia drugs are developed by each company?How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Methylmalonic Acidaemia?What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Methylmalonic Acidaemia therapeutics?What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?What are the clinical studies going on for Methylmalonic Acidaemia and their status?What are the key designations that have been granted to the emerging drugs?

Key Players

VectivBio AGCoA Therapeutics, Inc.HemoShear TherapeuticsModernaTX, Inc.

Key Products

VB-1197BBP-671HST5040mRNA-3705

Methylmalonic Acidaemia: Therapeutic Assessment

Phases

Late stage products (Phase III)Mid-stage products (Phase II)Early-stage product (Phase I) along with the details ofPre-clinical and Discovery stage candidatesDiscontinued & Inactive candidatesRoute of Administration

Products have been categorized under various ROAs such as

Intra-articularIntraocularIntrathecalIntravenousOphthalmicOralParenteralSubcutaneousTopicalTransdermalMolecule Type

Products have been categorized under various Molecule types such as

OligonucleotidePeptideSmall moleculeProduct Type

Methylmalonic Acidaemia Report Insights

Methylmalonic Acidaemia Pipeline AnalysisTherapeutic AssessmentUnmet NeedsImpact of Drugs

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/hidgfv

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo – https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/methylmalonic-acidaemia-pipeline-research-report-2023-comprehensive-insights-about-4-companies-and-4-pipeline-drugs-302014634.html

SOURCE Research and Markets